Patients with this profile are the most common participants included in the asthma studies for novel T2‐inflammation focused therapeutics, for example, anti‐IL‐13 and anti‐IL‐5 monoclonal antibodies.39, 40, 41, 42. Here, IL13 is linked to asthma.